PR5131 Chap.2 Coronary Syndromes and Secondary Prevention
Coronary Syndromes and Secondary Prevention
Coronary pharmacotherapy changes purpose across the acute event, discharge and long follow-up. During the acute phase, instability, reperfusion, thrombosis and immediate complications dominate. At discharge, the emphasis expands to recurrence prevention, safe transitions and counselling. At follow-up, the clinician has to reconstruct the current job of every medicine rather than copying the original list.
This chapter therefore reviews each therapy by indication, evidence of effectiveness, emerging harm, intended duration and priority. Antithrombotic benefit is balanced against bleeding rather than discussed in isolation, and a risk score is treated as an organiser rather than a substitute for judgement.
Lipid response, blood pressure, renal function, electrolytes, symptoms, adherence and adverse effects become evidence for continuation or change. Rescue therapy requires executable counselling, including what to do when symptoms persist. The final care plan distinguishes actions required now from reviews that can safely wait, while preserving secondary-prevention therapy whose benefit remains valuable.
A strong answer names the danger being prevented, the harm being watched and the review point that could alter the balance. This structure allows the same patient to be reconsidered as time, symptoms and competing risks change without assuming that chronology alone determines treatment.
What this chapter covers
- 01
Acute Coronary Syndromes
- 02
Chronic Coronary Syndromes
- 03
Antithrombotic Balance
- 04
Lipid Response
- 05
Rescue Nitrate Counselling
- 06
Ranked Medication Review
Worked example · free
Rank a post-infarction medication review
- 2Verify time-sensitive benefit and harm.
- 2Assess response and tolerance.
- 2Rank actions and monitoring.
Key terms
- Secondary Prevention
- Therapy intended to reduce recurrence after established cardiovascular disease.
- Ischaemic Risk
- The probability of recurrent thrombosis, infarction or related coronary harm.
- Bleeding Risk
- The probability and consequence of haemorrhage under antithrombotic treatment.
- Rescue Nitrate
- Short-acting nitrate used for rapid relief of an anginal episode.
Coronary Syndromes and Secondary Prevention FAQ
How should a long discharge list be reviewed?
Reconstruct each medicine by indication, intended duration, evidence of benefit, adverse effects and monitoring. Then rank what needs action today. This prevents a list from becoming a plan and reveals medicines whose purpose changed after the acute event.
Why are ischaemic and bleeding risks considered together?
Greater antithrombotic intensity can reduce recurrent ischaemia while increasing bleeding harm. Patient history, renal function, haemoglobin, concurrent anticoagulation and procedural context move the balance, so neither risk can be optimised without stating the other.
What makes counselling clinically useful?
Useful counselling connects mechanism to action. For rescue nitrate, explain when and how to use it, expected effects, safe posture, and the response to persistent symptoms. A medicine name without an escalation rule does not complete the care plan.
How should follow-up changes be prioritised?
Rank suspected irreversible harm and time-sensitive benefit first, then confirm the present indication for each therapy. State what can wait, what evidence is needed today and which valuable treatment the plan aims to preserve.
Exam move
Use a three-point timeline for every coronary case: acute event, discharge and follow-up. Under each point, write the current purpose of antithrombotic, lipid, ventricular-remodelling and symptom therapies. For every medicine, add an indication, one effectiveness measure, one important harm, a duration or review point and the patient factor most likely to alter it. This converts a list into a set of testable decisions.
Build an antithrombotic balance sheet with recurrent-ischaemia evidence on one side and bleeding evidence on the other. Change one variable at a time, such as a falling haemoglobin, new anticoagulation, renal decline or recurrent symptoms, and state how the priority changes. Do not let the exercise collapse into universal durations; practise asking which source or current plan supplies the duration in the case.
Add one benefit measure and one harm measure to lipid and blood-pressure therapies, then write the laboratory or symptom response that would justify adjustment. Rehearse rescue-nitrate counselling as spoken instructions: posture, administration, expected effects, persistent-symptom action and escalation. Practise turning a medication list into ranked decisions without reproducing any captured patient stem.
Use three labels beside each recommendation: now, confirm today or review later. Defend the first label with the irreversible harm or time-sensitive benefit that makes it urgent. When checking a model answer, strike out any recommendation that has no present indication and restore it only after stating the risk it addresses.
Compare two follow-up visits for the same invented patient so that monitoring data, rather than elapsed time by itself, drive the second plan. End by explaining which action cannot safely wait and which beneficial therapy you are trying to preserve. Keep a compact follow-up table with columns for new evidence, affected therapy, benefit at stake, harm at stake and next review.
Populate it from memory after each case and compare it with the longer answer. Missing cells expose recommendations that sound plausible but are not connected to a measurable reason or a scheduled reassessment. In timed revision, spend the first minute reconstructing the timeline, the second weighing benefit against harm and the third writing a ranked plan with monitoring.
This sequence mirrors the course demand for applied clinical reasoning rather than an unprioritised summary.
